160 related articles for article (PubMed ID: 21252141)
1. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
4. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
[TBL] [Abstract][Full Text] [Related]
5. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Mankhatitham W; Luaengniyomkul A; Manosuthi W
J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
[TBL] [Abstract][Full Text] [Related]
6. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
7. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
9. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Rajesh L; Karunaianantham R; Narayanan PR; Swaminathan S
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1179-85. PubMed ID: 19895208
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.
Abebe M; Kinde S; Belay G; Gebreegziabxier A; Challa F; Gebeyehu T; Nigussie P; Tegbaru B
BMC Res Notes; 2014 Jun; 7():380. PubMed ID: 24950924
[TBL] [Abstract][Full Text] [Related]
12. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.
Sinha S; Shekhar RC; Singh G; Shah N; Ahmad H; Kumar N; Sharma SK; Samantaray JC; Ranjan S; Ekka M; Sreenivas V; Mitsuyasu RT
BMC Infect Dis; 2012 Jul; 12():168. PubMed ID: 22846195
[TBL] [Abstract][Full Text] [Related]
13. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
15. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
18. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Sension M; Deckx H
AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
[TBL] [Abstract][Full Text] [Related]
19. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S
Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216
[TBL] [Abstract][Full Text] [Related]
20. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
